In Powerful Partnership Focused on Customers, Ribbon Bio and Scala Biodesign Advance Enzyme Innovation with Next-Generation Technologies
Ribbon Bio and Scala Biodesign, two emerging leaders in biotechnology, both led by women CEOs, have announced a new business collaboration focused on better delivering to customers enzymes that enable more powerful DNA synthesis. The companies are combining their expertise in DNA synthesis and enzyme design to demonstrate how stronger molecular tools can accelerate progress across the life sciences and expand the reach of their industry-leading tools to a broader set of customers worldwide.
Ribbon Bio Appoints Jeff Fitzgerald as Vice President, Global Head of Sales to Drive Commercial Growth and Strategic Expansion
Ribbon Bio GmbH, the DNA synthesis company, today announced that Jeff Fitzgerald has joined the company as Vice President, Global Head of Sales. With a proven track record in scaling commercial operations and leading teams across the industry, Mr. Fitzgerald will take on a pivotal role in accelerating Ribbon Bio’s next phase of growth.
Ribbon Bio Launches MiroSynth™ DNA Molecules to Unlock a New Era of Complex Synthetic DNA
Ribbon Bio GmbH, the DNA synthesis company, today announced the launch of MiroSynth™ DNA, its first commercial product designed to meet the growing demand for complex and highly-accurate synthetic DNA molecules. The product launch coincides with the Global Synthetic Biology Conference in San Jose, California, taking place May 5–8, 2025.
Ribbon Bio Appoints John Luckey as Chief Technology Officer
Ribbon Bio GmbH, the DNA synthesis company, announced today that John Luckey, Ph.D. has been appointed Chief Technology Officer. Dr. Luckey brings more than 25 years of technology development leadership experience in both start-up and global companies, advancing platforms and systems used in biomedical research and translational medicine, most recently at DNA Script.
